New York, USA, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Sjogren's Syndrome Market Size Increase with Significant CAGR by 2032, Predicts DelveInsight | Key Companies in the Market - Resolve, MorphoSys, Novartis, GlaxoSmithKline, Roche, BMS, TearSolutions, Incyte, Galapagos, Gilead Sciences
Sjogren's syndrome market dynamics are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies.
DelveInsight’s Sjogren's Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Sjogren's syndrome emerging drugs, market share of individual therapies, and current and forecasted Sjogren's syndrome market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Sjogren's Syndrome Market Report
- As per DelveInsight’s analysis, the Sjogren's syndrome market is anticipated to grow at a significant CAGR by 2032.
- As per DelveInsight estimates, the total cases of Sjogren’s syndrome in the 7MM were found to be 3.2 million in 2021. Among all the countries, the United States accounts for the largest population of Sjogren’s syndrome with 1.7 million cases in 2021.
- Leading Sjogren's syndrome companies such as Resolve Therapeutics, MorphoSys, Novartis, GlaxoSmithKline, Roche, Bristol Myers Squibb, TearSolutions, Incyte Corporation, Galapagos NV, Gilead Sciences, VIELABIO, Janssen Research & Development, LLC, Sanofi, Sylentis, S.A., Dompé Farmaceutici S.p.A, and others are developing novel Sjogren's syndrome drugs that can be available in the Sjogren's syndrome market in the coming years.
- Some of the key therapies for Sjogren's syndrome treatment include RSLV-132, VAY736, CFZ533, Belimumab, RO5459072, LOU-064, Abatacept, Lacripep, Parsaclisib, Filgotinib, GS-9876, VIB7734, Nipocalimab, SAR441344, Tivanisiran sodium ophthalmic solution, Oxervate, and others.
Discover which therapies are expected to grab the major Sjogren's syndrome market share @ Sjogren's Syndrome Market Report
Sjogren's Syndrome Overview
Sjogren's syndrome is a chronic autoimmune rheumatic disease that causes inflammation of the exocrine glands, primarily the salivary and lacrimal glands, as well as the nose, upper respiratory tract, oropharynx, and vagina in women. It is the result of a complicated interplay of various factors including immunological homeostasis and gene expression genetic and epigenetic regulation, age and gender, and environmental slander. Sjogren's syndrome is classified into two types: Primary Sjogren's syndrome and Secondary Sjogren's syndrome. Secondary Sjögren syndrome is associated with another underlying rheumatic disease or systemic autoimmune disease (most commonly systemic lupus erythematosus, rheumatoid arthritis, or scleroderma). Wet eyes and mouth are the most prevalent Sjogren's syndrome symptoms. The immune system also attacks other regions of the body, resulting in joint pain. Pain, edema, skin rashes, vaginal dryness, and other Sjogren's syndrome symptoms may occur.
Sjogren's Syndrome Epidemiology Segmentation
The Sjogren's syndrome epidemiology section provides insights into the historical and current Sjogren's syndrome patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The Sjogren's syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Sjogren's Syndrome Diagnosed Prevalent Cases
- Sjogren's Syndrome Gender-specific Cases
- Sjogren's Syndrome Type- Specific Cases
- Sjogren's Syndrome Severity-Specific Cases
Download the report to understand which factors are driving Sjogren's syndrome epidemiology trends @ Sjogren's Syndrome Epidemiological Insights
Sjogren's Syndrome Treatment Market
Currently, the Sjögren's syndrome treatment market size is mainly accounted by symptomatic treatment using local therapies like pilocarpine, cevimeline, topical fluoride, topical cyclosporine, autologous serum eye drops, and, systemic therapies like corticosteroids, hydroxychloroquine, immunosuppressants (Methotrexate (MTX), Cyclosporine A, Azathioprine, Leflunomide, and Mycophenolic acid). Furthermore, biological therapy using Rituximab is widely used in the US market. Local therapy is commonly used to treat sicca symptoms. The major Sjögren's syndrome treatment for dry eyes is tear substitution therapy, which consists of high-viscosity eye drops and gels combined with oral mucolytic medicines to break down mucus. Patients with Sjögren's syndrome with severe or resistant keratoconjunctivitis sicca may require a brief course of topical anti-inflammatory medications such as cyclosporine. In most refractory cases, autologous serum eye drops, and temporary occlusion of the puncta are used.
Systemic treatment is indicated when general symptoms (such as arthralgia) cannot be treated with local treatment or lifestyle changes, and when organ involvement is present. Corticosteroids and hydroxychloroquine are the most common non-biological medications used to treat Sjögren's syndrome. The use of prednisone to treat Sjögren's syndrome is based on its success in the treatment of other autoimmune illnesses. Corticosteroid treatment is typically indicated when there is severe cutaneous, pulmonary, renal, musculoskeletal, and/or neurological involvement. Long-term corticosteroid use has been linked to osteoporosis, diabetes, weight gain, and dyslipidemia.
To know more about Sjogren's syndrome clinical trials, visit @ Sjogren's Syndrome Treatment Drugs
Key Sjogren's Syndrome Therapies and Companies
- RSLV-132: Resolve Therapeutics
- VAY736: Novartis/MorphoSys
- CFZ533: Novartis
- Belimumab: GlaxoSmithKline
- RO5459072: Roche
- LOU-064: Novartis
- Abatacept: Bristol Myers Squibb
- Lacripep: TearSolutions
- Parsaclisib: Incyte Corporation
- Filgotinib: Galapagos NV /Gilead Sciences
- GS-9876: Gilead Sciences
- VIB7734: VIELABIO
- Nipocalimab: Janssen Research & Development, LLC
- SAR441344: Sanofi
- Tivanisiran sodium ophthalmic solution: Sylentis, S.A.
- Oxervate: Dompé Farmaceutici S.p.A
Learn more about the FDA-approved drugs for Sjogren's syndrome @ Drugs for Sjogren's Syndrome Treatment
Sjogren's Syndrome Market Dynamics
The Sjogren's syndrome market is in a state of evolution marked by several key dynamics. Firstly, heightened awareness among both healthcare professionals and patients has led to earlier diagnoses, expanding the patient population and creating a more significant Sjogren's syndrome market for treatment options. Secondly, advancements in biotechnology and immunology have resulted in the development of highly targeted biological therapies, such as monoclonal antibodies, which offer enhanced efficacy and improved quality of life for patients.
Moreover, the granting of orphan drug status in specific regions has incentivized pharmaceutical companies to invest in research and development, resulting in a surge of clinical trials and the introduction of innovative treatments. These developments have paved the way for a patient-centric approach to care, with personalized medicine gaining prominence. Genetic profiling and tailored treatments are becoming more common, ensuring that patients receive the most suitable interventions.
As competition in the Sjogren's syndrome market intensifies, it is fostering innovation and driving down costs, ultimately making treatments more accessible to a broader spectrum of patients. Additionally, the evolving regulatory environment, with a heightened focus on safety, efficacy, and real-world evidence, is shaping the approval and marketing of Sjogren's syndrome therapies.
However, several factors may impede the growth of the Sjogren's syndrome market. Despite growing awareness, there still exist substantial diagnostic delays and misdiagnoses, hindering early intervention. The complex and multifaceted nature of the disease often results in underdiagnosis, which poses a significant obstacle to market growth. Additionally, while advancements in biotechnology have yielded promising biological therapies, their high development costs can limit their accessibility to all patients. The availability of these therapies may be constrained by factors such as pricing, reimbursement policies, and healthcare disparities, which can impede their widespread adoption. The regulatory environment, while essential for ensuring safety and efficacy, can sometimes be a barrier, as stringent requirements and lengthy approval processes can delay the introduction of innovative treatments into the Sjogren's syndrome market.
| Sjogren's Syndrome Report Metrics | Details |
| Study Period | 2019–2032 |
| Sjogren's Syndrome Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Key Sjogren's Syndrome Companies | Resolve Therapeutics, MorphoSys, Novartis, GlaxoSmithKline, Roche, Bristol Myers Squibb, TearSolutions, Incyte Corporation, Galapagos NV, Gilead Sciences, VIELABIO, Janssen Research & Development, LLC, Sanofi, Sylentis, S.A., Dompé Farmaceutici S.p.A, and others |
| Key Sjogren's Syndrome Therapies | RSLV-132, VAY736, CFZ533, Belimumab, RO5459072, LOU-064, Abatacept, Lacripep, Parsaclisib, Filgotinib, GS-9876, VIB7734, Nipocalimab, SAR441344, Tivanisiran sodium ophthalmic solution, Oxervate, and others |
Scope of the Sjogren's Syndrome Market Report
- Therapeutic Assessment: Sjogren's Syndrome current marketed and emerging therapies
- Sjogren's Syndrome Market Dynamics: Attribute Analysis of Emerging Sjogren's Syndrome Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Sjogren's Syndrome Market Access and Reimbursement
Discover more about Sjogren's syndrome drugs in development @ Sjogren's Syndrome Clinical Trials
Table of Contents
| 1. | Sjogren's Syndrome Market Key Insights |
| 2. | Sjogren's Syndrome Market Report Introduction |
| 3. | Sjogren's Syndrome Market Overview at a Glance |
| 4. | Sjogren's Syndrome Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Sjogren's Syndrome Treatment and Management |
| 7. | Sjogren's Syndrome Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Sjogren's Syndrome Marketed Drugs |
| 10. | Sjogren's Syndrome Emerging Drugs |
| 11. | Seven Major Sjogren's Syndrome Market Analysis |
| 12. | Sjogren's Syndrome Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Sjogren's Syndrome Epidemiology Forecast
Sjogren's Syndrome Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted Sjogren's syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Sjogren's Syndrome Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Sjogren's syndrome companies, including Novartis, Horizon Therapeutics, Bristol-Myers Squibb, Rise Therapeutics, Resolve Therapeutics, Dompe Farmaceutici, among others.
Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key rheumatoid arthritis companies including Taisho Pharmaceuticals, R-Pharm, GlaxoSmithKline, Aclaris Therapeutics, Pfizer, Abivax, Bristol Myers Squibb, Oscotec, Genosco, Mesoblast, Pfizer Akros Pharma, Japan Tobacco, Abbvie, Horizon Therapeutics, Eli Lilly and Company, Taiho Pharmaceutical, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, SynAct Pharma, Cyxone, among others.
Rheumatoid Arthritis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key rheumatoid arthritis companies, including Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., KLUS Pharma Inc., Revolo Biotherapeutics, Lynk Pharmaceuticals, Beijing Baylx Biotech, Hope Biosciences, Kangstem Biotech, Celltex Therapeutics, I-Mab Biopharma Co. Ltd., Synermore Biologics Co., Ltd, Oryn Therapeutics, Arthrogen, Bayer, Amgen, Draconis Pharma, Biozeus, Landos Biopharma, Imcyse, Kymera Therapeutics, RedHill Biopharma, 4D Pharma, CV6 Therapeutics, VYNE Therapeutics, MyMD Pharmaceuticals, Brickell Biotech Inc, Worg Pharmaceuticals, Almirall, Standigm, Metrion Biosciences, Jnana Therapeutics, Silo Pharma, SFA Therapeutics, Neutrolis Therapeutics, Ahead Therapeutics, Fresenius Kabi, Kidswell Bio, BioXpress Therapeutics, CinnaGen, Alvotech, Hetero Biopharma, Shanghai Henlius Biotech, Cadila Pharmaceuticals, Innovent Biologics, Torrent Pharmaceuticals, Emcure Pharmaceuticals, mAbxience, Shanghai Junshi Biosciences, Enosi Therapeutics, among others.
Systemic Lupus Erythematosus Market
Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SLE companies including GlaxoSmithKline, AstraZeneca, Eli Lilly and Company, UCB Pharma, Biogen, Immupharma, Xencor, Idorsia Pharmaceuticals, Bristol-Myers Squibb (Celgene), Resolve Therapeutics, Genentech (Roche), Pfizer, among others.
Systemic Lupus Erythematosus Pipeline
Systemic Lupus Erythematosus Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key SLE companies, including AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, Janssen Research & Development, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma, Biocon Limited, Nektar Therapeutics, Hoffman-La-Roche, Sangamo therapeutics, Araim Pharmaceuticals, Chipscreen Biosciences, AstraZeneca/BenevolentAI, Reistone Biopharma, OMass Therapeutics, among others.
Other Trending Reports
Digestive System Fistula Market | Dementia With Diabetes Market | Leber's Hereditary Optic Neuropathy Market | Pecoma Market | Adamantinoma Market | Pegfilgrastim Biosimilar Insight | Functional Constipation Market | DDR Defective Tumors Market | Nephrotic Syndrome Pipeline | Pelizaeus-Merzbacher Disease Market | Hepatic Impairment Market | Primary Ciliary Dyskinesia Market | Surgical Bleeding Market | Radiotherapy-Induced Oral Mucositis Market | Relapsed Chronic Lymphocytic Leukemia CLL Market | Galactosemia Market | Glabellar Lines Market | Homozygous Familial Hypercholesterolemia Market | HR Positive/ HER2 Negative Breast Cancer Market | Lebers Hereditary Optic Neuropathy LHON Market | Nonalcoholic Fatty Liver Disease NAFLD Market | Orthotic Devices Market | Polypoidal Choroidal Vasculopathy Market | Sporadic Inclusion Body Myositis Market | Warm Autoimmune Hemolytic Anemia Market | Acid Sphingomyelinase Deficiency ASMD Market | B-Cell Chronic Lymphocytic Leukemia Market | Coccidioidomycosis Market | Frontotemporal Dementia Pipeline | Granulomatosis With Polyangiitis Market | Malignant Pleural Mesothelioma Market | Nocturnal Enuresis Market | Postmyocardial Infarction Syndrome Market | Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market | Typhoid Fever Market | Ventricular Dysfunction Market | Burkitt Lymphoma Market | Chronic Progressive Multiple Sclerosis Market | Emesis Market | Fenebrutinib Market | Gastric Neuroendocrine Tumors Market | Juvenile Rheumatoid Arthritis Market | Persistent Epithelial Defects Market | Post-Polycythemia Vera Myelofibrosis Market | Primary Mediastinal Large B-Cell Lymphoma Market | Spinocerebellar Ataxias Market | Systemic Inflammatory Response Syndrome Market | Triple Negative Breast Cancer Market | Visceral Pain Associated With GI Disorders Market | Adrenal Cortex Neoplasms Market | Adrenal Insufficiency Market | Artificial Lung Devices Market | Atopic Keratoconjunctivitis AKC Market | Autonomic Dysfunction Market | Bradycardia Treatment Devices Market | Bullous Pemphigoid Market | Cone Rod Dystrophy Market | Cutaneous Lupus Erythematosus Market | Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market | Dermal Regeneration Matrix Market | Heart Pump Devices Market | Hemiplegia Market | Hepatic Impairement Market | Immunologic Deficiency Syndrome Market | Implantable Infusion Pump Market | Menorrhalgia Market Size | Myocarditis Market | Myopia Treatment Devices Market | Ocular Hypertension Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
